SuperworthNewAmsterdam Pharma market cap NAMS
Share price times shares outstanding: what the whole company sells for, since 2023.
- Today, Oct 23, 2026
- $2.4B
- Highest close in our data
- $4.7B
- Nov 2025
NewAmsterdam Pharma is worth $2.4B at the close on Oct 23, 2026, at $19.71 a share.
That is down 41% over the last year.
Its highest close in our data was $4.7B in Nov 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $2.4B | $2.4B | $4.5B | −41% |
| 2025 | $4B | $1.7B | $4.7B | +67% |
| 2024 | $2.4B | $1B | $2.4B | +162% |
| 2023 | $911M | $546.5M | $1.3B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest NewAmsterdam Pharma's size, closest first, today.
| Company | Market cap |
|---|---|
| NAMSNewAmsterdam Pharma | $2.4B |
| PBHPrestige Consumer Healthcare | $2.3B |
| HRMYHarmony Biosciences | $2.1B |
| NRIXNurix Therapeutics | $2.8B |
| ANIPANI Pharmaceuticals | $1.7B |
| PAHCPhibro Animal Health | $1.6B |
| OGNOrganon | $3.6B |
| ANABAnaptysbio | $1.5B |
| LQDALiquidia | $3.8B |
| PCRXPacira BioSciences | $1.5B |
| ARQTArcutis Biotherapeutics | $3.9B |
| Peer median | $2.2B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on NewAmsterdam Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.